Form 4: Envista Holdings Corp: Stefan Nilsson Reports Acquisition of Shares and Derivative Securities
SEC Form 4 Filing
Stefan Nilsson, President of Nobel Biocare at Envista Holdings Corp, reports the acquisition of common stock, performance share units, and employee stock options.
Summary
- On February 25, 2025, Stefan Nilsson, President of Nobel Biocare at Envista Holdings Corp, reported transactions involving the company's securities.
- Nilsson acquired 10,290 shares of common stock.
- He also acquired 18,960 performance share units, which will vest based on the achievement of performance measures over a three-year period, with potential payout ranging from 0% to 200% of the reported amount.
- Additionally, Nilsson acquired 24,010 employee stock options with an exercise price of $20.66, vesting ratably over three years, expiring on 02/25/2035.
- Following these transactions, Nilsson beneficially owns 55,745 shares of common stock, 18,960 performance share units, and 24,010 employee stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions by an officer. The acquisitions suggest confidence, but it's not overwhelmingly positive.
Positives
- The acquisition of shares and derivative securities by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The performance share units will vest based on the achievement of identified performance measures over a three-year performance period, indicating a focus on future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and holdings, common in publicly traded companies. It provides transparency regarding the alignment of management's interests with those of shareholders.
Stakeholder Impact
- The reported transactions provide transparency to shareholders regarding the holdings of a key executive.
- The vesting of performance share units aligns management's interests with the company's performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Date of earliest transaction: Acquisition of common stock, performance share units, and employee stock options. |
| 02/27/2025 | Date of signature on the report. |
| 02/25/2035 | Expiration date of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.